Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 2
1954 1
1957 1
1970 2
1973 2
1974 3
1975 1
1978 1
1982 1
1983 2
1984 1
1985 1
1986 1
1987 1
1988 3
1989 4
1991 3
1992 2
1994 4
1995 4
1996 10
1997 7
1998 11
1999 8
2000 9
2001 17
2002 13
2003 18
2004 12
2005 25
2006 31
2007 31
2008 33
2009 38
2010 66
2011 55
2012 55
2013 50
2014 52
2015 43
2016 42
2017 58
2018 55
2019 62
2020 70
2021 77
2022 69
2023 69
2024 55

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,035 results

Results by year

Filters applied: . Clear all
Page 1
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. Among authors: de miguel m. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Jhaveri K, et al. Among authors: de miguel mj. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. Ann Oncol. 2023. PMID: 37597578 Free PMC article. Clinical Trial.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Among authors: de miguel m. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS. Garralda E, et al. Among authors: de miguel m. ESMO Open. 2022 Dec;7(6):100639. doi: 10.1016/j.esmoop.2022.100639. Epub 2022 Dec 6. ESMO Open. 2022. PMID: 36493599 Free PMC article.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: de miguel m. Lancet Oncol. 2024 Jun;25(6):707-719. doi: 10.1016/S1470-2045(24)00140-2. Epub 2024 May 3. Lancet Oncol. 2024. PMID: 38710187 Clinical Trial.
The future of oncology therapeutics.
Mansinho A, Boni V, de Miguel M, Calvo E. Mansinho A, et al. Among authors: de miguel m. Expert Rev Anticancer Ther. 2017 Jul;17(7):563-565. doi: 10.1080/14737140.2017.1331131. Epub 2017 May 22. Expert Rev Anticancer Ther. 2017. PMID: 28504011 No abstract available.
Honey as a Complementary Medicine.
Miguel MG, Antunes MD, Faleiro ML. Miguel MG, et al. Integr Med Insights. 2017 Apr 24;12:1178633717702869. doi: 10.1177/1178633717702869. eCollection 2017. Integr Med Insights. 2017. PMID: 28469409 Free PMC article. Review.
Polymer-vesicle association.
Antunes FE, Marques EF, Miguel MG, Lindman B. Antunes FE, et al. Among authors: miguel mg. Adv Colloid Interface Sci. 2009 Mar-Jun;147-148:18-35. doi: 10.1016/j.cis.2008.10.001. Epub 2008 Oct 21. Adv Colloid Interface Sci. 2009. PMID: 19058777 Review.
Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer.
Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramon-Patino JL, Escudero FJ, Miguel M, Pelaez-Garcia A, Hernandez A, Feliu J, Hardisson D, Redondo A. Mendiola M, et al. Among authors: miguel m. Int J Mol Sci. 2023 Sep 23;24(19):14468. doi: 10.3390/ijms241914468. Int J Mol Sci. 2023. PMID: 37833916 Free PMC article.
Angioleiomioma oral: relato de um caso e revisão dos achados atuais.
da Silva LAB, de Medeiros AMC, de Oliveira PT, da Silveira ÉJD, Miguel MCDC. da Silva LAB, et al. Among authors: miguel mcdc. J Vasc Bras. 2017 Jan-Mar;16(1):68-72. doi: 10.1590/1677-5449.000417. J Vasc Bras. 2017. PMID: 29930628 Free PMC article. Portuguese.
1,035 results